Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 10/20 | 0.87 |
| ▸ | CYP2C9 | P11712 | 6/20 | 0.84 |
| ▸ | TSHR | P16473 | 4/20 | 0.76 |
| ▸ | MEN1 | O00255 | 1/20 | 0.76 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.76 |
| ▸ | CYP2C19 | P33261 | 6/20 | 0.66 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.66 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.65 |
| ▸ | HIF1A | Q16665 | 3/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.61 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.61 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.59 |
| ▸ | USP2 | O75604 | 1/20 | 0.58 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.58 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3088233 | 0.93 | MEN1 (0.87) | CYP3A4CYP2C9TSHRMEN1KMT2A | |
| SCHEMBL3095008 | 0.93 | CYP2C9 (0.83) | CYP3A4CYP2C9TSHRMEN1KMT2A | |
| SCHEMBL639215 | 0.87 | CYP3A4 (0.68) | CYP3A4CYP2C9TSHRMEN1KMT2A | |
| SCHEMBL3096735 | 0.87 | CYP2C9 (1.00) | CYP3A4CYP2C9TSHRMEN1KMT2A | |
| SCHEMBL484916 | 0.82 | ITGB3 (0.68) | CYP3A4CYP2C9TSHRMEN1KMT2A | |
| SCHEMBL30042024 | 0.82 | CYP3A4 (0.67) | CYP3A4CYP2C9TSHRMEN1KMT2A | |
| SCHEMBL16611629 | 0.81 | CYP2C9 (0.64) | CYP3A4CYP2C9TSHRCYP2C19HSD17B10 | |
| SCHEMBL640636 | 0.79 | ITGB3 (0.67) | CYP3A4CYP2C9TSHRMEN1KMT2A | |
| SCHEMBL11955978 | 0.79 | CYP3A4 (0.65) | CYP3A4CYP2C9TSHRMEN1KMT2A | |
| SCHEMBL30333555 | 0.79 | CYP2C9 (0.61) | CYP3A4CYP2C9TSHRMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100234340-A1 | Substituted Spiroamide Compounds | GRUENENTHAL GMBH (DE) | 2010-09-16 | — | — | US | claimed |
| US-8357717-B2 | Spiro group-containing amide compounds having bradykinin 1 receptor (B1R) activity | GRUENENTHAL GMBH (DE) | 2013-01-22 | — | — | US | disclosed |
| US-20100234340-A1 | Substituted Spiroamide Compounds | GRUENENTHAL GMBH (DE) | 2010-09-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100234340-A1 | Substituted Spiroamide Compounds | BDKRB1, BDKRB2, AVPR1B | CYP3A4 1215/4885CYP2C9 351/4885TSHR 704/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.